Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GNPAT | O15228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30798035 | 0.97 | MME (0.41) | MMECA2CA1ENPEPECE1 | |
| SCHEMBL30859432 | 0.96 | MME (0.40) | MMECA2CA1ENPEPECE1 | |
| SCHEMBL30477911 | 0.95 | MME (0.39) | MMECA2CA1ENPEPECE1 | |
| SCHEMBL30038078 | 0.94 | MME (0.39) | MMECA2CA1ENPEPECE1 | |
| SCHEMBL29510840 | 0.94 | MME (0.38) | MMEENPEPGNPAT | |
| SCHEMBL31707374 | 0.93 | MME (0.38) | MMEENPEPECE1GNPAT | |
| SCHEMBL29598237 | 0.92 | MME (0.40) | MMECA2CA1ENPEPGNPAT | |
| SCHEMBL30477912 | 0.91 | MME (0.40) | MMECA2CA1ENPEPECE1 | |
| SCHEMBL29373629 | 0.91 | ECE1 (0.39) | MMECA2CA1ECE1 | |
| SCHEMBL29886675 | 0.91 | BACE1 (0.40) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295762-A1 | COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-09-25 | — | — | US | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| WO-2024163874-A2 | STABLE AND CONTROLLED RELEASE FORMULATIONS OF NEUREGULIN-4 ANALOGS | AVEXEGEN THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| WO-2023183287-A2 | COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-09-28 | — | — | WO | claimed |
| CN-115047120-B | Method for analyzing and detecting dansyl chloride derivative of dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023150693-A2 | NEUREGULIN-4 ANALOGS AND METHODS OF USING THEREOF IN DISEASE TREATMENT | AVEXEGEN THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| WO-2022168062-A1 | VARIANTS OF HYPERTHERMOPHILIC CARBOXYLESTERASE FOR POLYMER SYNTHESIS | UNIVERSIDADE DE COIMBRA (PT) | 2022-08-11 | — | — | WO | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-20260139023-A1 | NOVEL IRISIN PEPTIDES AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139263-A1 | MODIFICATION OF TRANSCRIPTIONAL REPRESSOR BINDING SITE IN NF-YC4 PROMOTER FOR INCREASED PROTEIN CONTENT AND RESISTANCE TO STRESS | IOWA STATE UNIV RESEARCH FOUNDATION INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132175-A1 | METHODS AND COMPOSITIONS TO MODULATE T CELL METABOLISM, FUNCTION, AND FATE | CORNELL UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4737575-A2 | MODIFICATION OF TRANSCRIPTIONAL REPRESSOR BINDING SITE IN NF-YC4 PROMOTER FOR INCREASED PROTEIN CONTENT AND RESISTANCE TO STRESS | Iowa State University Research Foundation, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20220062389-A1 | METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5 | DANA-FARBER CANCER INSTITUTE, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220062423-A1 | EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220049247-A1 | MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP) | CRISPR THERAPEUTICS AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220047722-A1 | MATERIALS AND METHODS FOR TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 1 (SCA1) AND OTHER SPINOCEREBELLAR ATAXIA TYPE 1 PROTEIN (ATXN1) GENE RELATED CONDITIONS OR DISORDERS | CRISPR THERAPEUTICS AG (CH) | 2022-02-17 | — | — | US | disclosed |
| WO-2022020353-A2 | METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139023-A1 | NOVEL IRISIN PEPTIDES AND METHODS OF USE THEREOF | MSTN, MYOF, TNNC1 | MME 3101/4885CA2 4749/4885CA1 4195/4885 |
| US-20260139263-A1 | MODIFICATION OF TRANSCRIPTIONAL REPRESSOR BINDING SITE IN NF-YC4 PROMOTER FOR INCREASED PROTEIN CONTENT AND RESISTANCE TO STRESS | YBX1, RELA, NFRKB | MME 2575/4885CA2 3766/4885CA1 3917/4885 |
| US-20250295762-A1 | COMPOSITE BIOACTIVE COMPOSITIONS AND APPLICATIONS THEREOF | BMP2, BMP1, MATR3 | MME 3208/4885CA2 156/4885CA1 56/4885 |
| US-20260132175-A1 | METHODS AND COMPOSITIONS TO MODULATE T CELL METABOLISM, FUNCTION, AND FATE | TAGLN2, ICOS, CALR | MME 2651/4885CA2 321/4885CA1 966/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | MME 2240/4885CA2 2395/4885CA1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.